Tscan Therapeutics (TCRX) Stock: Why The Price Surged 17.83%

Apr 12th, 2022 7:05 EST
  • The stock price of Tscan Therapeutics Inc (NASDAQ: TCRX) increased by 17.83% in the most recent trading session. This is why.

The stock price of Tscan Therapeutics Inc (NASDAQ: TCRX) – a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer – increased by 17.83% in the most recent trading session. Investors are responding positively to TScan Therapeutics announcing the appointment of Leiden Dworak, CPA, MBA, as Vice President, Finance. Mr. Dworak brings to TScan over a decade of experience in financial infrastructure implementation and operations management in early/mid-stage biotech.

Prior to joining TScan, Dworak was the Vice President, Head of Financial Planning and Analysis and Business Operations at AVROBIO where he implemented a financial infrastructure and developed processes to enable the annual operating plan, strategic plan, and financial reporting. Before joining AVROBIO, Dworak was a Director at Moderna where he was a key strategic business partner across multiple therapeutic areas and the finance lead for global vaccines business development. Prior to that, Dworak held positions of increasing responsibility for various biotech and pharmaceutical companies including Merrimack Pharmaceuticals, SeraCare Life Sciences (now LGC Clinical Diagnostics), and Boston Scientific Corporation. Dworak is a certified public accountant (CPA), inactive non-reporting license and a MBA from Indiana University, Bloomington, Indiana.


“We are pleased to welcome Leiden to TScan at such an exciting time as we advance our lead liquid tumor TCR-T therapy programs focused on the prevention of relapse in patients undergoing HCT into clinical development. His experience in financial planning and analysis will be valuable as we strategically enter our next phase of growth and maximize our balance sheet to support key development milestones into 2024.”

— David Southwell, President and Chief Executive Officer

“I am excited to join the TScan team as we advance our mission to create life-changing T cell therapies for patients with cancer. I am grateful to be working alongside a seasoned leadership team and look forward to applying my experience and expertise to support the financial well-being and continued advancement of the Company’s pipeline of liquid and solid tumor candidates.”

— Leiden Dworak

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.

Link to Source

Recent Publications of TScan Therapeutics- Inc.

Leave a Comment

SOTD Membership

Register by Email

Already a member? Sign In